Enter what the patient has. Both verdicts update as you click, with the reason for each and what would change the 2024 answer. It assumes the presentation is typical for its category and that there is no better explanation.
Typical lesions in 2 or more regions. 2017 has 4 regions. 2024 adds the optic nerve as a fifth. In progressive onset, 2 or more cord lesions count as 2 regions (2024).
2017: enhancing and non-enhancing lesions together, a new lesion on follow-up, or a second attack. OCB can substitute. 2024: one new T2 lesion, one enhancing lesion, or a clinical attack. No longer mandatory.
CSF-restricted oligoclonal bands (2 or more). In 2024, a kFLC index of 6.1 or more is interchangeable with OCB.
A thin dark line or dot running centrally through the lesion, seen in two planes on T2* or SWI. Positive with 6 or more CVS lesions. With fewer than 10 lesions, CVS lesions must be the majority. Under 18: more than 50% of T2 lesions.
A rim around at least two thirds of a non-enhancing lesion on phase images. In 2024 it counts only when a single region is involved, paired with DIT or positive CSF. Not for RIS.
A short intrinsic MRI lesion, an OCT inter-eye difference (pRNFL 6 µm or more, GCIPL 4 µm or more), or VEP delay or asymmetry. Not if chiasmal, perineural, or longitudinally extensive.
2024 strongly recommends a spinal cord lesion, positive CSF, or CVS Select-6 before confirming MS. Vascular risk: hypertension, smoking, diabetes, hyperlipidemia, or macrovascular disease.
The same framework applies. Test MOG-IgG in all children under 12. Do not apply the criteria at an ADEM presentation: wait for a second typical attack or new lesions more than 90 days later.
One year of progression plus 2 of 3: a typical brain lesion (periventricular, juxtacortical, or infratentorial), 2 or more cord lesions, or CSF-restricted OCB.